Search
Teva Pharmaceutical Industries Ltd
TEVAAdd to Watchlist
39.370USD
-0.690-1.72%
Market hours 09/22, 12:04（ET）
45.87BMarket Cap
31.97P/E TTM
About {index_name} Teva Pharmaceutical Industries Ltd Company
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Teva Pharmaceutical Industries Ltd Profile
Ticker SymbolTEVA
Company nameTeva Pharmaceutical Industries Ltd
IPO dateFeb 06, 2087
CEOFrancis (Richard D)
Number of employees33892
Security typeDepository Receipt
Fiscal year-endFeb 06
Address124 Dvora Hanevi'a St.
CityTEL AVIV-YAFO
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryIsrael
Postal code6944020
Phone97239148213
Websitehttps://www.tevapharm.com/
Ticker SymbolTEVA
IPO dateFeb 06, 2087
CEOFrancis (Richard D)
Company Executives of Teva Pharmaceutical Industries Ltd
Name
Name/Position
Position
Shareholding
Change
Mr. Amir Elstein
Mr. Amir Elstein
Independent Director
Independent Director
2.12M
+0.68%
Mr. Richard D. Francis
Mr. Richard D. Francis
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.18M
+0.59%
Mr. Mark Sabag
Mr. Mark Sabag
Executive Vice President - International Markets Commercial
Executive Vice President - International Markets Commercial
885.93K
+11.77%
Dr. Sol J. Barer, Ph.D.
Dr. Sol J. Barer, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
448.01K
+4.85%
Mr. Richard Daniell
Mr. Richard Daniell
Executive Vice President - European Commercial
Executive Vice President - European Commercial
183.56K
-16.34%
Dr. Eric A. Hughes
Dr. Eric A. Hughes
Executive Vice President - Global R&D, Chief Medical Officer
Executive Vice President - Global R&D, Chief Medical Officer
134.88K
+20.14%
Mr. Gerald M. (Jerry) Lieberman
Mr. Gerald M. (Jerry) Lieberman
Independent Director
Independent Director
130.15K
+11.13%
Mr. Evan Lippman
Mr. Evan Lippman
Executive Vice President - Business Development
Executive Vice President - Business Development
130.04K
+33.98%
Ms. Rosemary A. (Rose) Crane
Ms. Rosemary A. (Rose) Crane
Independent Director
Independent Director
127.74K
+11.35%
Dr. Perry D. Nisen, M.D., Ph.D.
Dr. Perry D. Nisen, M.D., Ph.D.
Independent Director
Independent Director
119.81K
+12.10%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Amir Elstein
Mr. Amir Elstein
Independent Director
Independent Director
2.12M
+0.68%
Mr. Richard D. Francis
Mr. Richard D. Francis
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.18M
+0.59%
Mr. Mark Sabag
Mr. Mark Sabag
Executive Vice President - International Markets Commercial
Executive Vice President - International Markets Commercial
885.93K
+11.77%
Dr. Sol J. Barer, Ph.D.
Dr. Sol J. Barer, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
448.01K
+4.85%
Mr. Richard Daniell
Mr. Richard Daniell
Executive Vice President - European Commercial
Executive Vice President - European Commercial
183.56K
-16.34%
Dr. Eric A. Hughes
Dr. Eric A. Hughes
Executive Vice President - Global R&D, Chief Medical Officer
Executive Vice President - Global R&D, Chief Medical Officer
134.88K
+20.14%
FAQs
Who are the top five shareholders of Teva Pharmaceutical Industries Ltd?
The top five shareholders of Teva Pharmaceutical Industries Ltd are: Mr. Amir Elstein
How many institutions hold shares of Teva Pharmaceutical Industries Ltd (TEVA)?
As of 2026Q1, 1226 institutions hold shares of Teva Pharmaceutical Industries Ltd, with a combined market value of approximately 725.07M, accounting for 62.27% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 9191465.00.
What is the biggest source of revenue for Teva Pharmaceutical Industries Ltd?
In 2026Q1, the Generic products business generated the highest revenue for Teva Pharmaceutical Industries Ltd, amounting to 2.10B and accounting for 50.77% of total revenue.